Patents Assigned to Nippon Medical School Foundation
-
Publication number: 20220235375Abstract: A method for producing a nucleic acid-encapsulated adeno-associated virus (AAV) hollow particle, comprising the following steps: (1) preparing a linear nucleic acid fragment comprising a sequence for A region and a sequence for D? region in an AAV inverted terminal repeat (ITR) (i.e., an AD sequence) or a sequence complementary to the AD sequence and a target gene sequence; (2) introducing the nucleic acid fragment prepared in step (1) into a cell capable of producing an AAV hollow particle; and (3) culturing the cell obtained in step (2).Type: ApplicationFiled: July 2, 2020Publication date: July 28, 2022Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, TAKARA BIO INC.Inventors: Takashi OKADA, Junichi MINENO, Hideto CHONO
-
Publication number: 20220127606Abstract: Provided are a complex that comprises a nucleic acid-containing nanoparticle and a hollow particle of a non-enveloped virus, a method for producing the complex, and a pharmaceutical composition comprising the complex.Type: ApplicationFiled: January 29, 2020Publication date: April 28, 2022Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON MEDICAL SCHOOL FOUNDATIONInventors: Takashi Okada, Hiromi KINOH, Yoshitsugu AOKI, Shin'ichi TAKEDA
-
Publication number: 20210246173Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.Type: ApplicationFiled: April 29, 2021Publication date: August 12, 2021Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.Inventors: Takashi OKADA, Hironori OKADA, Hiromi KINOH, Tatsuji ENOKI, Toshikazu NISHIE, Junichi MINENO
-
Publication number: 20210228205Abstract: An automatic needle mover (1) for moving a medical threaded needle includes: two shafts (a first shaft (11) and a second shaft (12)) extending in the same direction and slidable relative to each other along a longitudinal direction; a needle holding portion (a second needle support portion (22)) provided on one end side of the second shaft (12); a needle-receiving portion (a first needle support portion (21)) provided on one end side of the first shaft (11); and a handle (30) serving as a control portion for controlling the sliding of the two shafts. The needle holding portion has a first groove portion provided in a first claw portion protruding in a direction intersecting the longitudinal direction of the shafts. The needle-receiving portion has a second groove portion provided in a second claw portion protruding in a direction intersecting the longitudinal direction of the shafts.Type: ApplicationFiled: May 30, 2019Publication date: July 29, 2021Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, NIPPON MEDICAL SCHOOL FOUNDATIONInventors: Ryu NAKADATE, Susumu OGURI, Makoto HASHIZUME, Akio MORITA
-
Publication number: 20210205285Abstract: The present invention provides a therapeutic agent or a prophylactic agent of dementia containing xanthine oxidase inhibitor such as a compound represented in formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: February 17, 2017Publication date: July 8, 2021Applicants: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, Nippon Medical School Foundation, Teijin Phama LimitedInventors: Takeshi NISHINO, Shinsuke KATO, Masako KATO, Hidenori SUZUKI, Ken OKAMOTO
-
Patent number: 11028131Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.Type: GrantFiled: January 29, 2018Date of Patent: June 8, 2021Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.Inventors: Takashi Okada, Hironori Okada, Hiromi Kinoh, Tatsuji Enoki, Toshikazu Nishie, Junichi Mineno
-
Publication number: 20210087560Abstract: An object of the present invention is to provide a vector capable of oligodendrocyte-specifically suppressing expression of the PLP1 gene for treating PMD caused by abnormality of the PLP1 gene, and a promoter and miRNA therefor, and a pharmaceutical composition comprising the vector. The oligodendrocyte-specific promoter of the present invention comprises a nucleic acid having a sequence identity of at least 90% to a nucleotide sequence set forth in SEQ ID NO: 1. The miRNA of the present invention specific to the PLP1 gene comprises a pair of nucleotide sequences consisting of a specific antisense sequence and sense sequence.Type: ApplicationFiled: February 6, 2019Publication date: March 25, 2021Applicants: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON MEDICAL SCHOOL FOUNDATION, DAIICHI SANKYO COMPANY, LIMITEDInventors: Ken Inoue, Heng Li, Takashi Okada, Yu Ohki, Makoto Koizumi
-
Publication number: 20200284792Abstract: The present invention aims to develop a method capable of evaluating T cell immune function. A method for evaluating T cell immune function including detecting and quantifying soluble PD-L1 having a binding ability to PD-1, and an ELISA system used for detecting and quantifying bsPD-L1, including a carrier with a solid-phased PD-1 protein, a means for reacting the carrier and a test sample, and a means for detecting and m quantifying soluble PD-L1 bound to the carrier as bsPD-L1.Type: ApplicationFiled: September 7, 2018Publication date: September 10, 2020Applicants: UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, JAPAN, NIPPON MEDICAL SCHOOL FOUNDATIONInventors: Yoshiko IWAI, Masahiro TAKEUCHI, Tomomitsu DOI
-
Publication number: 20200002384Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.Type: ApplicationFiled: January 29, 2018Publication date: January 2, 2020Applicants: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.Inventors: Takashi OKADA, Hironori OKADA, Hiromi KINOH, Tatsuji ENOKI, Toshikazu NISHIE, Junichi MINENO
-
Publication number: 20190330705Abstract: A method of detecting somatic mutations of tumor marker genes includes recovering a peripheral blood mononuclear cell layer from a blood sample collected from a subject and examining whether or not a nucleic acid derived from tumor marker genes having somatic mutations is detected from DNA included in the peripheral blood mononuclear cell layer.Type: ApplicationFiled: July 9, 2019Publication date: October 31, 2019Applicants: TOPPAN PRINTING CO., LTD., NIPPON MEDICAL SCHOOL FOUNDATIONInventors: Shiro KITANO, Takeshi Yamada, Goro Takahashi, Takuma Iwai, Koki Takeda
-
Publication number: 20190307761Abstract: The inventors found that postsurgical recurrence and/or metastasis of cancer is suppressed by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery. Accordingly, the disclosure provides an agent for suppressing recurrence and/or metastasis of cancer, comprising a beta-blocker and being administered during a perioperative period of cancer surgery.Type: ApplicationFiled: June 29, 2018Publication date: October 10, 2019Applicants: ONO PHARMACEUTICAL CO., LTD., NIPPON MEDICAL SCHOOL FOUNDATIONInventors: Atsuhiro SAKAMOTO, Tatsuaki OKAMURA, Tomohiro HARADA
-
Patent number: 10413546Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.Type: GrantFiled: February 23, 2016Date of Patent: September 17, 2019Assignees: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, NIPPON MEDICAL SCHOOL FOUNDATION, NIPPON CHEMIPHAR CO., LTD.Inventors: Takeshi Nishino, Shinsuke Kato, Masako Kato, Hidenori Suzuki, Ken Okamoto
-
Publication number: 20180135138Abstract: A method for evaluating a health condition, includes: measuring a test amount of cell free DNA per unit amount of a body fluid sample collected from a subject after tumor resection; and comparing the measured test amount of cell free DNA with a reference value so as to evaluate a health condition of the subject. The reference value is one of a predetermined threshold value; an amount of cell free DNA per unit amount of a body fluid sample collected from the subject before tumor resection; an amount of cell free DNA per unit amount of a body fluid sample collected from the subject between 1 week and 3 months after tumor resection; and an amount of cell free DNA per unit amount of a body fluid sample collected from the subject by the time of collecting the body fluid sample for measuring the test amount of cell free DNA.Type: ApplicationFiled: January 12, 2018Publication date: May 17, 2018Applicants: TOPPAN PRINTING CO., LTD., NIPPON MEDICAL SCHOOL FOUNDATIONInventors: Shiro Kitano, Takeshi Yamada, Takuma Iwai
-
Publication number: 20180117047Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.Type: ApplicationFiled: February 23, 2016Publication date: May 3, 2018Applicants: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, NIPPON MEDICAL SCHOOL FOUNDATION, NIPPON CHEMIPHAR CO., LTD.Inventors: Takeshi NISHINO, Shinsuke KATO, Masako KATO, Hidenori SUZUKI, Ken OKAMOTO
-
Patent number: 9133484Abstract: A transfection agent is provided that has lower toxicity and can be applied in the clinical setting. The transfection agent comprises a peptide surfactant.Type: GrantFiled: August 26, 2009Date of Patent: September 15, 2015Assignees: 3-D MATRIX, LTD., NIPPON MEDICAL SCHOOL FOUNDATIONInventors: Daizo Yoshida, Jiro Takei
-
Patent number: 9097693Abstract: The invention provides a method for simple, rapid and inexpensive analysis of drugs such as nicotine and other drugs which are accumulated in biological samples of addictive drugger of tobacco, stimulant drug and the like. The method comprises the steps of introducing the biological sample into an injection needle, inserting the needle into an injector of a chromatograph and injecting a carrier into the needle to conduct chromatography treatment.Type: GrantFiled: March 14, 2006Date of Patent: August 4, 2015Assignees: SHINWA CHEMICAL INDUSTRIES, LTD., NATIONAL UNIVERSITY CORPORATION TOYOHASHI UNIVERSITY OF TECHNOLOGY, NIPPON MEDICAL SCHOOL FOUNDATIONInventors: Hiroo Wada, Kiyokatsu Jinno, Yoshihiro Saito, Youkichi Ohno, Makiko Hayashida
-
Patent number: 8944991Abstract: The invention provides a surgical device for endoscopic surgery having the function of temporarily storing liquid (a first function), the function of keeping a physical space for surgery and a sufficient endoscopic field (a second function), and the function of protecting organs (a third function), and an insertion device for inserting the surgical device into a body. [Solving Means] The surgical device for endoscopic surgery is an inter-organ spacer (10) including liquid holding means (1) formed of a porous soft material having the ability to temporarily store liquid and the ability to retain its shape. The insertion device for inserting the inter-organ spacer into a body includes a tubular holder capable of holding the inter-organ spacer for endoscopic surgery.Type: GrantFiled: December 26, 2008Date of Patent: February 3, 2015Assignees: Nippon Medical School Foundation, Hogy Medical Co., Ltd.Inventors: Yoshiharu Nakamura, Satoshi Matsumoto, Toshiki Inoue
-
Patent number: 8684938Abstract: A biological condition evaluation apparatus determines a symptom of a heart abnormality based on at least one index calculated from a heartbeat interval and/or a pulse interval. The apparatus determines whether it is in a referential period where an amount of change in the index is comparatively small. The apparatus determines whether a plurality of conditions are satisfied or not in an evaluation period set after the referential period. One condition is that an amount of change in the index in the evaluation period is greater than that observed during the referential period. Another condition is that a rate of change in the index is equal to or greater than a predetermined threshold value. The apparatus determines that there is a symptom of a heart abnormality, when both the conditions are satisfied.Type: GrantFiled: January 18, 2010Date of Patent: April 1, 2014Assignees: DENSO CORPORATION, Nippon Medical School Foundation, Toyota Jidosha Kabushiki KaishaInventors: Kazuhiro Sakai, Shinji Nanba, Takao Katoh, Motohisa Osaka, Yoshitaka Fuwamoto
-
Patent number: 8548578Abstract: A living body state monitor apparatus includes: a living body information acquisition device to acquire living body information containing an electrocardiography waveform and a pulse waveform from a user; an irregular heartbeat detection section to detect an irregular heartbeat from the electrocardiography waveform; and a pulse wave feature quantity extraction section to extract a pulse wave feature quantity from a pulse wave corresponding to the irregular heartbeat. Further, a living body state determination section is included to determine a danger degree on user's living body state using both of (A) information on kind and/or continued time period of an irregular heartbeat detected by the irregular heartbeat detection section, and (B) a pulse wave feature quantity extracted by the pulse wave feature quantity extraction section, and/or a variation of the extracted pulse wave feature quantity.Type: GrantFiled: October 13, 2011Date of Patent: October 1, 2013Assignees: DENSO CORPORATION, Toyota Jidosha Kabushiki Kaisha, Nippon Medical School FoundationInventors: Shinya Matsunaga, Shinji Nanba, Tsuyoshi Nakagawa, Kouki Futatsuyama, Takao Katoh, Hiroshige Murata, Hiroshi Hayashi, Motohisa Osaka, Minoru Makiguchi
-
Patent number: 8318792Abstract: A method for treating amyotrophic lateral sclerosis is disclosed wherein a compound having xanthine dehydrogenase inhibiting activity is administered.Type: GrantFiled: July 13, 2007Date of Patent: November 27, 2012Assignees: Nippon Medical School Foundation, National University Corporation Tottori UniversityInventors: Takeshi Nishino, Yasuko Abe, Shinsuke Kato